Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Dorn

Surgery Abingdon, VA Doctor of Osteopathy

NPI 1649477209 CMS profile 29041

16000 Johnston Memorial Dr, Suite 101, Abingdon, VA 24211

Open in the dashboard

General payments

$13,380

57 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Dorn of Abingdon, VA is reported in the CMS Open Payments database as having received $13,380 across 57 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,619 5
2024 General $10,323 33
2023 General $924 4
2022 General $39 2
2021 General $26 3
2020 General $209 4
2019 General $239 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Dorn
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Matthew Dorn were reported at $1,619. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Matthew Dorn Surgery median Middle half National median
2019 $239 $253 $82–$1,521 $163
2020 $209 $131 $40–$706 $114
2021 $26 $168 $50–$904 $132
2022 $39 $224 $76–$1,218 $149
2023 $924 $253 $82–$1,255 $160
2024 $10,323 $279 $90–$1,381 $164
2025 $1,619 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $11,807 32 payments
  2. Stryker Corporation $848 1 payment
  3. Pacira Pharmaceuticals Incorporated $153 1 payment
  4. Portola Pharmaceuticals, Inc. $126 4 payments
  5. FUJIFILM Medical Systems USA, Inc. $101 1 payment
  6. Davol Inc. $38 1 payment
  7. Braintree Laboratories, Inc. $34 1 payment
  8. Shire North American Group Inc $32 2 payments
  9. W. L. Gore & Associates, Inc. $28 1 payment
  10. AbbVie, Inc. $25 1 payment
  11. Other $189 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $7,819 8 payments
  2. Travel and Lodging $3,154 7 payments
  3. Food and Beverage $2,398 41 payments
  4. Gift $9 1 payment
Products named General payments · program years 2019–2025
  1. DAVINCI XI $7,536 6 payments
  2. Da Vinci Surgical System $4,271 26 payments
  3. 1688 $848 1 payment
  4. EXPAREL $153 1 payment
  5. ANDEXXA $126 4 payments
  6. ESD - Core Endoscopy $101 1 payment
  7. Phasix Mesh $38 1 payment
  8. SUTAB $34 1 payment
  9. GATTEX $32 2 payments
  10. GORE SYNECOR Biomaterial $28 1 payment
  11. Other $214 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

836

Median for General Surgery: 59

Drug cost

$26,253

Median for General Surgery: $393

Branded share of claims

32.9%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 21 $11,175
Erythromycin Erythromycin Base Brand 15 $5,286
Sucralfate Generic 126 $3,031
Pantoprazole Sodium Generic 285 $1,976
Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 100 $1,698
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 16 $985
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 70 $610
Methocarbamol Generic 49 $429
Ondansetron Hcl Generic 58 $334
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 16 $180

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 120 billing codes

Paid by Medicare

$114,263

Medicare's payments for the services billed

Medicare patients

338

Average age 73

Services billed

793

154 women, 184 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Diabetes 41%
Chronic kidney disease 37%
Ischemic heart disease 36%
Depression 30%
COPD 28%
Atrial fibrillation 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

57 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record